SEATCA Urges Reconsideration of E-Cigarette Regulation in Philippines

Aug.07.2024
SEATCA Urges Reconsideration of E-Cigarette Regulation in Philippines
SEATCA urges Philippine lawmakers to reconsider E-cigarette regulation following Supreme Court ruling favoring FDA oversight.

According to a report by Vera Files on August 7, the Southeast Asia Tobacco Control Alliance (SEATCA) has called on Philippine legislators to reconsider the "Vaporized Nicotine and Non-Nicotine Products Regulation Act," which gives the Department of Trade and Industry regulatory power over electronic smoking devices (ESDs). This call comes following a Supreme Court ruling which clearly stated that such products should be regulated by the Food and Drug Administration (FDA).


It has been reported that on January 26, 2022, the Philippine Congress passed the "Vaporized Nicotine and Non-Nicotine Products Regulation Act" (Republic Act No. 11900). The newly elected President, Ferdinand Marcos Jr., allowed the law to automatically take effect on July 25, despite calls from health organizations and medical groups to veto the bill in order to protect youth from the dangers of tobacco and other e-cigarette products.


The law will lower the age restriction for the use of e-cigarettes from 21 to 18, allowing online advertising and sales of new types of e-cigarette products, and placing regulation under the Department of Commerce and Industry instead of the FDA. The Department of Commerce and Industry issued a temporary suspension of online sales of e-cigarette products on July 20, stating the need to "protect youth and prioritize public health.


In a decision announced on July 23, the Supreme Court stated:


All products that affect health, including tobacco products, should fall under the jurisdiction of the FDA to ensure their safety, efficacy, purity, and quality.


The Philippines Department of Health welcomed the decision on July 30, stating that it is an important step in preventing the tobacco industry from bypassing existing policies and enhancing the ability of enforcement agencies to reduce health risks associated with tobacco consumption.


The Executive Director of SEATCA, Dr. Ulysses Dorotheo, pointed out:


Due to the harmful effects of e-cigarettes on health, the FDA is the appropriate agency regulating these products. We must actively protect the authority of the health department to regulate the tobacco industry and reject any attempts to weaken or question this authority.


The former Health Minister Jaime Galvez Tan stated:


This is a milestone victory in our fight to reduce tobacco consumption and its deadly impact on Filipinos, especially young people.


In the latest ruling written by Supreme Court Associate Justice Marvic Leonen, the Court reiterated its 2021 decision affirming the FDA's authority to regulate tobacco products. The Court rejected the motion for reconsideration filed by the Philippine Tobacco Institute (PTI) and Albay 1st District Representative Edcel Lagman, and further dismissed the Tobacco Inter-Agency Committee's claim of exclusive authority over tobacco products.


We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Cochrane 2026 Update Adds Nine Trials, Keeps High-Certainty Finding That Nicotine E-Cigarettes Improve Quit Rates Over NRT
Cochrane 2026 Update Adds Nine Trials, Keeps High-Certainty Finding That Nicotine E-Cigarettes Improve Quit Rates Over NRT
Cochrane’s 2026 update of its living review on electronic cigarettes for smoking cessation included 80 randomized controlled trials involving 29,861 adult smokers, with nine trials added in this update. The review retained its high-certainty conclusion that nicotine e-cigarettes increase smoking cessation rates compared with nicotine replacement therapy. In absolute terms, about 10 in 100 people using nicotine e-cigarettes may quit smoking for at least six months, compared with about 6 in 100 using NRT. The review found no clear difference in serious adverse event rates between the two groups, while longer-term safety and the relative effectiveness of newer device types remain less certain.
Sep.07
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Eleftheria (Ria) Kioupritzi, a biopharmaceutical professional with more than 15 years of experience, has joined Philip Morris International as Director Scientific Affairs within Corporate Affairs. She previously served at Roche as Senior Scientific Communications Director for Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy. Her earlier career also covered competitive intelligence, clinical and regulatory monitoring, pipeline development and launch preparation. During her time working in Roche's SMA field, Evrysdi passed through several U.S. FDA milestones, including its initial approval, an expanded indication for younger infants and approval of a tablet formulation. Public records do not show that Kioupritzi herself led the FDA submissions.
Sep.22
Exclusive Analysis | Smoore H1 Revenue Rises 19.9% Amid Growth Concentration, Profit Pressure and Slowing Momentum
Exclusive Analysis | Smoore H1 Revenue Rises 19.9% Amid Growth Concentration, Profit Pressure and Slowing Momentum
Smoore’s first-half 2026 revenue rose 19.9%, but the results revealed growing structural risks beneath the headline growth. Heat-not-burn contributed about 61% of incremental revenue and remains driven largely by one core customer, while traditional vaping markets diverged, own-brand growth slowed and China enterprise revenue declined further. Gross profit and adjusted profit lagged revenue growth, while second-quarter revenue growth slowed to about 1.9%, putting greater focus on the quality, concentration and sustainability of Smoore’s expansion.
Capital Markets
Aug.20
From Product Innovation to Integrated Solutions: NEXTECH Expands Its Global Heated Tobacco Solutions
From Product Innovation to Integrated Solutions: NEXTECH Expands Its Global Heated Tobacco Solutions
NEXTECH launched its NEXE Pro circumferential-heating tobacco stick globally at InterTabac 2026, as the company expands from product innovation into broader heated tobacco solutions. Amid intensifying competition across global HTP markets, NEXTECH is strengthening its R&D, manufacturing and pre-launch support capabilities to serve different types of business customers.
Industry Insight
Sep.15
2Firsts Hosts China Market Forum at InterTabac as Global Industry Attention to China’s Tobacco Sector Deepens
2Firsts Hosts China Market Forum at InterTabac as Global Industry Attention to China’s Tobacco Sector Deepens
On September 16, 2Firsts hosted a China-focused industry forum during InterTabac in Dortmund, bringing together more than 30 participants from North America, Europe, India, South Korea and other markets. The session covered traditional tobacco, next-generation products, exports, technology, regulation and supply chains, while examining how China’s tobacco sector operates, where its transformation may be heading, and why its growing role matters increasingly to companies across the global tobacco and nicotine industry.
Sep.21
Product | HQD SiSA 80K Enters the U.S. Market With a Hookah-Inspired Approach to the High-Capacity Disposable Segment
Product | HQD SiSA 80K Enters the U.S. Market With a Hookah-Inspired Approach to the High-Capacity Disposable Segment
The HQD SiSA 80K Hookah Disposable Vape has appeared across U.S. and cross-border online retail channels. The device comes prefilled with 28ml of e-liquid, uses a 5% nicotine salt configuration and carries a brand claim of up to 80,000 puffs. Beyond puff count, the product differentiates itself through hookah-inspired features including adjustable airflow, a flowing-water sound effect and flavor options associated with traditional hookah consumption.
Aug.18